8-K: CooperCompanies Appoints New Director, Resolves Activist Standoff

CooperCompanies has appointed Walter M. Rosebrough, Jr. to its Board of Directors and entered into a cooperation agreement with activist investor Browning West, LP.

Summary

• The Cooper Companies, Inc. (the Company) entered into a letter agreement with Browning West, LP on December 22, 2025.
• Walter M. Rosebrough, Jr. was appointed to the Company's Board of Directors and the Corporate Governance and Nominating Committee, effective January 3, 2026.
• The Company will nominate and support Mr. Rosebrough's election at the 2026 annual meeting of stockholders.
• The Board will conduct a search for one additional independent director with medical technology experience, subject to Browning West's approval, to be appointed by June 30, 2026.
• The Board size will be limited to ten directors during the Cooperation Period.
• The Board will provide due and serious consideration to appointing Mr. Rosebrough as Chairman of the Board on or prior to the conclusion of the Cooperation Period.
• Browning West has agreed to customary standstill restrictions and voting commitments during the Cooperation Period, which extends until 30 days prior to the notice deadline for stockholder nominations for the 2027 annual meeting.
• Browning West beneficially owns approximately 4.0% (7,778,724 common shares) of the Company's issued and outstanding common shares.
• The Company will reimburse Browning West for $400,000 in out-of-pocket expenses related to its involvement and the agreement.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the constructive resolution with an activist investor, the appointment of a highly experienced independent director, and a clear commitment to enhancing corporate governance and long-term shareholder value. This indicates a proactive step towards stability and strategic improvement.

Positives

• Appointment of Walter M. Rosebrough, Jr., a highly experienced medical device industry executive, to the Board and Nominating Committee.
• Resolution of potential conflict with activist investor Browning West through a cooperation agreement, ensuring board stability and strategic alignment.
• Commitment to further board refreshment by identifying and appointing an additional independent director with medical technology experience.
• Mr. Rosebrough's proven track record includes leading STERIS plc to a 10-fold total return and an 18% annualized return over 14 years, significantly outperforming the S&P 500.
• The agreement includes a standstill provision and voting commitments from Browning West, providing a period of stability for the Company's governance.

Risks

• Forward-looking statements are subject to risks and uncertainties, including market conditions and other factors detailed in the Company's Annual Report on Form 10-K, which could cause actual results to differ materially.
• The Company's obligations under the agreement could terminate if Browning West breaches the agreement and fails to cure it within ten business days.
• Browning West's obligations under the voting and standstill provisions could terminate if the Company breaches the agreement and fails to cure it within ten business days.

Future Outlook

The Company aims to support its strategic vision and ongoing focus on delivering long-term value for shareholders, with the new board appointments positioning Cooper to drive critical initiatives to unlock sustained long-term value.

Management Comments

• Colleen Jay, Incoming Chair of the Board of CooperCompanies, stated: "We are pleased to welcome Walt to our Board. He brings decades of leadership experience in the medical device manufacturing and healthcare industries, and his proven track record delivering sustainable growth will support our strategic vision and ongoing focus of delivering long-term value for shareholders."
• Usman S. Nabi, Co-Founder and Chief Investment Officer of Browning West, commented: "Cooper has significant long-term potential, and we are pleased to have aligned on a constructive path forward with the Cooper Board. We believe Walts appointment along with the Companys commitment to additional Board refreshment position Cooper to drive the critical initiatives required to unlock sustained long-term value for all shareholders."

Industry Context

The medical device industry is dynamic, requiring strong leadership and strategic oversight to navigate innovation, regulatory changes, and market competition. The appointment of an experienced executive like Mr. Rosebrough, particularly one with a background in infection prevention and support systems, aligns with the industry's focus on specialized healthcare solutions. The resolution with an activist investor highlights the increasing scrutiny on corporate governance and shareholder value creation within the sector.

Comparison to Industry Standards

• Walter M. Rosebrough, Jr.'s tenure as CEO of STERIS plc (NYSE: STE) from 2007 to 2021 saw the company's stock generate a 10-fold total return, an 18% annualized return, significantly outperforming the S&P 500's 10% annualized return during the same period.
• Under Mr. Rosebrough's leadership, STERIS's market capitalization increased by over $20 billion, demonstrating substantial value creation in the medical device sector.
• His prior experience includes nearly two decades at Hill-Rom Holdings, Inc., where he held senior executive positions, including President and CEO of Support Systems International and President and CEO of Hill-Rom, further solidifying his expertise in medical technology leadership.
• Mr. Rosebrough currently serves as Independent Chair on the Board of Varex Imaging (NASDAQ: VREX), indicating ongoing engagement with industry governance best practices.

Management Changes

Corporate Governance

Related Party Transactions

• There are no related party transactions of the kind described in Item 404(a) of Regulation S-K in which Mr. Rosebrough was a participant, other than the Agreement itself.

Stakeholder Impact

• Shareholders: Likely to benefit from improved corporate governance, strategic alignment, and a more experienced board, potentially leading to enhanced long-term value.
• Management: Gains stability and a clear path forward following the resolution of activist engagement, with new expertise added to the board.
• Employees: No direct impact mentioned, but improved company performance and stability can indirectly benefit employees.
• Customers/Suppliers: No direct impact mentioned.

Next Steps

• The Company will nominate Walter M. Rosebrough, Jr. for election to the Board at the 2026 annual meeting of stockholders.
• The Board will engage a nationally recognized independent board search firm to identify one additional independent director with medical technology experience, targeting appointment by June 30, 2026.
• The Board will provide due and serious consideration to appointing Mr. Rosebrough as Chairman of the Board on or prior to the conclusion of the Cooperation Period.

Key Dates

Recommendation

The filing details a significant corporate governance update, including the appointment of a highly qualified independent director and a cooperation agreement with an activist investor. This resolution is a positive step towards board stability and strategic alignment, which can be beneficial for long-term shareholder value. However, as this is primarily a governance announcement rather than a financial performance report, a 'hold' recommendation is appropriate. Investors should monitor the execution of the strategic initiatives and the impact of the new board composition on future financial results before making a stronger directional call.

Keywords

Corporate Governance, Board Appointment, Activist Investor, Cooperation Agreement, Medical Device, Director Nomination, Shareholder Value, SEC Filing, COO